Dual checkpoint therapy in poor-prognosis liver cancer: tolerable, with modest responses

Design

Phase 3b, single-arm, open-label study

Population

111 adults with unresectable HCC and Child-Pugh B7/B8, ECOG 2 or main portal vein thrombosis

Primary outcome

Grade 3/4 treatment-related adverse events within 6 months and objective response rate

Effect

Grade 3/4 events 19.8% (12.9–28.5); ORR 14.4% (8.5–22.4); Child-Pugh B ORR 6.8%

SIERRA, a single-arm phase 3b study published in the Journal of Hepatology on 6 October, gave a single dose of tremelimumab with ongoing durvalumab to 111 adults with unresectable hepatocellular carcinoma who would usually be excluded from trials: Child-Pugh B7 or B8 liver function (44), performance status 2 (47), or main trunk portal vein thrombosis (20).

Within six months, grade 3 or 4 treatment-related adverse events occurred in 19.8%, similar across groups. Objective response was 14.4% overall: 6.8% with Child-Pugh B, 21.3% with performance status 2 and 15.0% with main portal vein thrombosis.

These patients make up a large share of those seen in practice, including in India, where liver cancer often presents late on a background of decompensated liver disease. The data suggest the regimen is tolerable here, but responses in Child-Pugh B are uncommon.

Without a comparison group, the study cannot show survival benefit. Decisions for Child-Pugh B patients still rest heavily on liver reserve, and best supportive care remains appropriate for many.

• Consider tremelimumab-durvalumab for selected patients with performance status 2 or main portal vein thrombosis.
• Expect low response rates in Child-Pugh B liver function; discuss goals carefully.
• Monitor liver function closely; decompensation can mimic or mask immune toxicity.
• Grade 3 or 4 toxicity affected about one in five within six months.
• Cost will limit access for many patients in India.

Why it matters

It provides prospective data for the patients most often seen and least often studied.

Don't overread it

This was single-arm, with no comparator; it cannot show the regimen extends survival in these patients.

The statistics, in plain English

The response rate of 6.8% in Child-Pugh B (95% CI 1.4 to 18.7) comes from 44 patients, so the true figure could be anywhere from very rare to about one in five. Small subgroups give wide ranges.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.